Buvidal Forum: Long-Acting Injectable Buprenorphine: Exploring Benefits and Challenges

On Thursday 1st August 2024 we hosted an online forum on ‘Long-Acting Injectable Buprenorphine: Exploring Benefits and Challenges’. It proved to be a highly engaging and informative session, and provided a platform for commissioners, clinicians, and data managers to share ideas and knowledge from different perspectives.

The key topics explored within the forum where:

• Funding and planning of Buvidal provision across treatment services
• Clinical management of offering Buvidal as OST option
• Reporting requirements and measuring outcomes 

By hosting this forum, ILLY were able to gain a good understanding of the key challenges and benefits of offering long-acting injectable buprenorphine as a treatment option – including cost considerations, the need for additional training for healthcare providers and navigating the regulatory hurdles. 

It is through collaborative forums such as this that we can continue to develop and improve the processes around this important treatment option – from both a therapeutic perspective and data capture perspective, and support services to further evidence the efficacy of Buvidal as treatment option. 

We are grateful to all participants for their valuable contributions. With your support, we can continue making a positive impact in our communities and we look forward to continuing these important conversations. 

If you would like to view the recording of the Buvidal Forum please reach out to our account management team at accountmanagement@illycorp.com or 0204 566 5727.